| Atrophy (14) |  |
| Bleeding (66) | |
| Chest pain (4) | |
| Disability (104) | |
| Dystrophy (3) | |
| Edema (3) | |
| Fever (40) | |
| Fibrosis (56) | |
| Headache (11) | |
| Hyperplasia (4) | |
| Hypertrophy (3) | |
| Malignancy (12) | |
| Preeclampsia (11) | |
| Sclerosis (17) | |
| Sickness (10) | |
| Ulcer (28) | |
| Atrophy (14) | |
| Bleeding (66) | |
| Chest pain (4) | |
| Disability (104) | |
| Dystrophy (3) | |
| Edema (3) | |
| Fever (40) | |
| Fibrosis (56) | |
| Headache (11) | |
| Hyperplasia (4) | |
| Hypertrophy (3) | |
| Malignancy (12) | |
| Preeclampsia (11) | |
| Sclerosis (17) | |
| Sickness (10) | |
| Ulcer (28) | |
which multiple members were blind from birth due to conditions such as Leber congenital amaurosis, cone-rod dystrophy,
first mapped the gene causing North carolina macular dystrophy on chromosome 6 in 1992. The current findings ultimately required an international team of 20 investigators using data from the Human genome Project
a private British biopharmaceutical company focused on the development of therapies for retinal dystrophies. e are leading the way in the development of an effective gene therapy treatment for choroideremia,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011